Claudio Bravo, MD
Associate Professor
Medicine
School of Medicine

His primary contributions include describing the role of adenylyl cyclase type 5 blockade in animal models of heart failure and studying outcomes of patients with advanced heart failure using continuous flow LVADs. His research focuses on discovering new molecular mechanisms and pharmacological targets for treating right ventricular failure using multi-omics. Clinically, Dr. Bravo's goal is to provide top-notch medical care to his patients and to advance the field.

• The Impact of the 2018 Allocation System Change on Patients Bridged With Durable Left Ventricular Assist Device: An Updated UNOS Registry Analysis.
  ASAIO journal (American Society for Artificial Internal Organs : 1992) 2024 Braghieri L, Olivas-Martinez A, Silvestri EG, Karatasakis A, Li S, Mahr C, Bravo C
• Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices.
  Frontiers in cardiovascular medicine 2022 Dimarakis I, Callan P, Khorsandi M, Pal JD, Bravo CA, Mahr C, Keenan JE
• Explainable Machine Learning Analysis of Right Heart Failure After Left Ventricular Assist Device Implantation.
  ASAIO journal (American Society for Artificial Internal Organs : 1992) 2022 Bahl A, Qureshi B, Zhang K, Bravo C, Mahr C, Li S
• Right heart failure after left ventricular assist device: From mechanisms to treatments.
  Frontiers in cardiovascular medicine 2022 Bravo CA, Navarro AG, Dhaliwal KK, Khorsandi M, Keenan JE, Mudigonda P, O'Brien KD, Mahr C
• Anthropogenic influence on surface changes at the Olivares glaciers; Central Chile.
  The Science of the total environment 2022 Barandun M, Bravo C, Grobety B, Jenk T, Fang L, Naegeli K, Rivera A, Cisternas S, Münster T, Schwikowski M
• The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support.
  Journal of clinical medicine 2022 Berardi C, Bravo CA, Li S, Khorsandi M, Keenan JE, Auld J, Rockom S, Beckman JA, Mahr C
• Projected increases in surface melt and ice loss for the Northern and Southern Patagonian Icefields.
  Scientific reports 2021 Bravo C, Bozkurt D, Ross AN, Quincey DJ
• Systematic Assessment of Online Health Information for Coronary Revascularization.
  JAMA internal medicine 2021 Hameed I, Hameed NUF, Oakley CT, Gambardella I, Bravo C, Angiolillo DJ, Gaudino M
• Presence of Intracardiac Thrombus at the Time of Left Ventricular Assist Device Implantation Is Associated With an Increased Risk of Stroke and Death.
  Journal of cardiac failure 2021 Bravo CA, Fried JA, Willey JZ, Javaid A, Mondellini GM, Braghieri L, Lumish H, Topkara VK, Kaku Y, Witer L, Takayama H, Takeda K, Sayer G, Uriel N, Demmer RT, Naka Y, Yuzefpolskaya M, Colombo PC
• Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure.
  Kidney international reports 2020 Yamada T, Ueyama H, Chopra N, Yamaji T, Azushima K, Kobayashi R, Kinguchi S, Urate S, Suzuki T, Abe E, Saigusa Y, Wakui H, Partridge P, Burger A, Bravo CA, Rodriguez MA, Ivey-Miranda J, Tamura K, …
• Metabolomic Profiling of Left Ventricular Diastolic Dysfunction in Women With or at Risk for HIV Infection: The Women's Interagency HIV Study.
  Journal of the American Heart Association 2020 Bravo CA, Hua S, Deik A, Lazar J, Hanna DB, Scott J, Chai JC, Kaplan RC, Anastos K, Robles OA, Clish CB, Kizer JR, Qi Q
• Testing e-mail content to encourage physicians to access an audit and feedback tool: a factorial randomized experiment.
  Current oncology (Toronto, Ont.) 2019 Vaisson G, Witteman HO, Chipenda-Dansokho S, Saragosa M, Bouck Z, Bravo CA, Desveaux L, Llovet D, Presseau J, Taljaard M, Umar S, Grimshaw JM, Tinmouth J, Ivers NM
• Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis.
  Vascular 2018 Olmedo W, Villablanca PA, Sanina C, Walker J, Weinreich M, Brevik J, Avendano R, Bravo CA, Romero J, Ramakrishna H, Babaev A, Attubato M, Hernandez-Suarez DF, Cox-Alomar P, Pyo R, Krishnan P, Wiley J
• Meta-Analysis and Trial Sequential Analysis Comparing Percutaneous Ventricular Assist Devices Versus Intra-Aortic Balloon Pump During High-Risk Percutaneous Coronary Intervention or Cardiogenic Shock.
  The American journal of cardiology 2018 Rios SA, Bravo CA, Weinreich M, Olmedo W, Villablanca P, Villela MA, Ramakrishna H, Hirji S, Robles OA, Mahato P, Gluud C, Bhatt DL, Jorde UP
• A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion.
  Journal of molecular and cellular cardiology 2018 Zhang J, Levy D, Oydanich M, Bravo CA, Yoon S, Vatner DE, Vatner SF
• Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease.
  Heart (British Cardiac Society) 2018 Bravo CA, Hirji SA, Bhatt DL, Gluud C, Faxon DP, Ohman EM, Kaneko T, Engstrøm T, Høfsten DE, Brennan JM
• Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management.
  Journal of cardiothoracic and vascular anesthesia 2017 Stawiarski K, Kataria R, Bravo CA, Villablanca P, Mohananey D, Narasimhan S, Ramakrishna H
• Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease.
  The Cochrane database of systematic reviews 2017 Bravo CA, Hirji SA, Bhatt DL, Kataria R, Faxon DP, Ohman EM, Anderson KL, Sidi AI, Sketch MH, Zarich SW, Osho AA, Gluud C, Kelbæk H, Engstrøm T, Høfsten DE, Brennan JM
• High Titer of Circulating Antiglutamic Acid Decarboxylase Antibodies in a Patient with Cerebellar Ataxia and Type 1 Diabetes.
  Connecticut medicine 2017 Kataria R, Fernandes S, Lebastchi J, Bravo CA, Sena KN
• Response to Letter to the Editor on "Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?".
  The Journal of pharmacology and experimental therapeutics 2016 Bravo CA, Vatner DE, Vatner SF
• A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion.
  The Journal of pharmacology and experimental therapeutics 2016 Bravo CA, Vatner DE, Pachon R, Zhang J, Vatner SF
• Sudden cardiac death as a presentation of anomalous origin of the left coronary artery from pulmonary artery in a young adult.
  European heart journal. Acute cardiovascular care 2014 Pachon R, Bravo C, Niemiera M
• Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway.
  Circulation 2013 Lai L, Yan L, Gao S, Hu CL, Ge H, Davidow A, Park M, Bravo C, Iwatsubo K, Ishikawa Y, Auwerx J, Sinclair DA, Vatner SF, Vatner DE
• Metabolomic analysis of two different models of delayed preconditioning.
  Journal of molecular and cellular cardiology 2012 Bravo C, Kudej RK, Yuan C, Yoon S, Ge H, Park JY, Tian B, Stanley WC, Vatner SF, Vatner DE, Yan L
• Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase.
  American journal of physiology. Heart and circulatory physiology 2012 Iwatsubo K, Bravo C, Uechi M, Baljinnyam E, Nakamura T, Umemura M, Lai L, Gao S, Yan L, Zhao X, Park M, Qiu H, Okumura S, Iwatsubo M, Vatner DE, Vatner SF, Ishikawa Y